Table 4.
Comparison of mean and median Skindex-16 scores for patients experiencing dermatological adverse events
| Skindex-16 domains | Current study | Current study | Current study | Joshi et al.4 | Rosen et al.14 | Rosen et al.14 |
|---|---|---|---|---|---|---|
| Papulopustular eruption | Xerosis | Pruritus | EGFRI AEs |
Targeted therapy AEs | Non-targeted therapy AEs | |
| n = 30 | n = 24 | n = 21 | n = 67 | n = 163 | n = 120 | |
| Symptoms | ||||||
| Mean (SD) | 27.2 (26.4) | 22.9 (26.5) | 35.6 (28.9) | 45.3a,b,c | ||
| Median (95 % CI) | 20.8 (12.5–33.3) | 16.7 (0.00–29.2) | 29.2 (20.8–37.5) | 37.5 (29.2–54.2)b,c | 39.6 (25.0–45.8)b,c | |
| Emotions | ||||||
| Mean (SD) | 17.2 (21.9) | 14.7 (19.3) | 21.4 (24.2) | 50.0a,b,c,d | ||
| Median (95 % CI) | 9.53 (4.77–21.4) | 9.53 (0.00–21.4) | 14.3 (4.77–26.2) | 50.0 (40.5–57.1)b,c,d | 38.1 (30.4–47.6)b,c,d | |
| Functioning | ||||||
| Mean (SD) | 10.0 (17.1) | 7.23 (14.3) | 10.5 (15.7) | 31.3a,b,c,d | ||
| Median (95 % CI) | 0.00 (0.00-10.2) | 0.00 (0.00–3.34) | 3.34 (0.00–16.7) | 16.7 (8.2–26.7)b,c,d | 13.3 (3.3–20.0)b,c | |
Joshi et al. [4] displayed mean scores while Rosen et al. [14] displayed median scores. Therefore, in the current study, both are displayed to make comparison possible
AE adverse event
aNo standard deviations were given in Joshi et al. [4]
bA statistically significant result compared with patients from the current study experiencing papulopustular eruption
cA statistically significant result compared with patients from the current study experiencing xerosis
dA statistically significant result compared with patients from the current study experiencing pruritus